BASi (Bioanalytical Systems, Inc.) (NASDAQ:BASI) today announced the launch of Culex
NxT, the latest generation of the Company’s proprietary in vivo automated sampling system. The Company is now taking orders for Culex NxT and expects to begin shipping in January.
Developed by BASi to collect pharmacokinetic and pharmacodynamic data, the Culex system can automatically collect blood, bile, metabolites, dialysates and more from awake and freely moving animals as small as mice and as large as swine. The system is used by nine of the world’s top ten pharmaceutical companies, universities, and contract research organizations.
"Scientists choose Culex over manual sampling because it delivers better data, which leads to better decision-making," said Candace Rohde-Johnson, director of BASi's Instruments Division. "Incorporating innovative hardware and software improvements, the new Culex NxT has the same small footprint, robust design and ease of use of the original, providing its users peace of mind when away from the lab. Culex’s ability to run experiments around the clock versus just during business hours significantly increases our clients' efficiency and productivity in the early stages of drug discovery, including safety pharmacology."
Rohde-Johnson continued, "Culex NxT incorporates what we have learned from Culex enthusiasts in industry and academia who share best practices, attend annual user meetings and provide their insights online. The improved tubing sets, optics, wireless notifications, quieter operation and in-line glucose monitoring are just some of the improvements built on this foundation, solidifying Culex as the preferred instrumentation for automated sampling. We've also made it easy for current owners to seamlessly and cost-effectively upgrade their existing systems."
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit
for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.